Published in Pharmacol Rev on March 01, 2003
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev (2006) 5.28
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J (2006) 2.17
15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med (2004) 1.84
Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci (2009) 1.57
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One (2008) 1.44
Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol (2009) 1.42
Resolution of acute inflammation in the lung. Annu Rev Physiol (2013) 1.42
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci (2009) 1.42
Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A (2005) 1.41
Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol (2012) 1.37
Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev (2011) 1.29
12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med (2008) 1.21
Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem (2008) 1.17
CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmacol (2005) 1.17
Anaphylactic shock depends on endothelial Gq/G11. J Exp Med (2009) 1.16
Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci U S A (2006) 1.08
Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Front Immunol (2012) 1.06
Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol (2014) 1.03
A novel rat lipoxin A4 receptor that is conserved in structure and function. Br J Pharmacol (2003) 1.00
Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther (2008) 1.00
GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors. BMC Bioinformatics (2008) 0.95
Annexin A1 and the regulation of innate and adaptive immunity. Front Immunol (2012) 0.94
Bioactive lipids in Trypanosoma cruzi infection. Adv Parasitol (2011) 0.93
Leukotriene B4 augments and restores Fc gammaRs-dependent phagocytosis in macrophages. J Biol Chem (2010) 0.93
CysLT1 receptor-induced human airway smooth muscle cells proliferation requires ROS generation, EGF receptor transactivation and ERK1/2 phosphorylation. Respir Res (2006) 0.92
Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach. BMC Struct Biol (2010) 0.91
Leukotrienes in atherosclerosis: new target insights and future therapy perspectives. Mediators Inflamm (2010) 0.90
CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS One (2013) 0.89
Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol (2013) 0.87
Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2. J Immunol (2011) 0.86
Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes. PLoS One (2013) 0.86
Differential inhibitory effects of CysLT(1) receptor antagonists on P2Y(6) receptor-mediated signaling and ion transport in human bronchial epithelia. PLoS One (2011) 0.85
Expression of eicosanoid receptors subtypes and eosinophilic inflammation: implication on chronic rhinosinusitis. Respir Res (2006) 0.84
5-Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor-induced cell migration through Tiam1 upregulation and Rac1 activation. Cancer Sci (2014) 0.84
Leukotriene D4 increases the excitability of capsaicin-sensitive nasal sensory nerves to electrical and chemical stimuli. Br J Pharmacol (2008) 0.82
Transforming growth factor β1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1. J Neuroinflammation (2012) 0.79
The contractile action of leukotriene B4 in the guinea-pig lung involves a vascular component. Br J Pharmacol (2004) 0.79
Enhanced cysteinyl-leukotriene type 1 receptor expression in T cells from house dust mite-allergic individuals following stimulation with Der p. J Immunol Res (2015) 0.79
Cooperative and redundant signaling of leukotriene B4 and leukotriene D4 in human monocytes. Allergy (2011) 0.79
A role for inflammatory mediators in heterologous desensitization of CysLT1 receptor in human monocytes. J Lipid Res (2009) 0.78
Intercellular Lipid Mediators and GPCR Drug Discovery. Biomol Ther (Seoul) (2013) 0.77
Genetic effect of CysLTR2 polymorphisms on its mRNA synthesis and stabilization. BMC Med Genet (2009) 0.77
Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Thorax (2005) 0.77
Systems biology approach to the dissection of the complexity of regulatory networks in the S. scrofa cardiocirculatory system. Int J Mol Sci (2013) 0.77
Leukotrienes are upregulated and associated with human T-lymphotropic virus type 1 (HTLV-1)-associated neuroinflammatory disease. PLoS One (2012) 0.76
The effects of montelukast on tissue inflammatory and bone marrow responses in murine experimental allergic rhinitis: interaction with interleukin-5 deficiency. Immunology (2007) 0.75
Seminal Fluid-Mediated Inflammation in Physiology and Pathology of the Female Reproductive Tract. J Immunol Res (2016) 0.75
The role of Lipoxin A4 in Cystic Fibrosis Lung Disease. Comput Struct Biotechnol J (2013) 0.75
BML-111 Protected LPS/D-GalN-Induced Acute Liver Injury in Rats. Int J Mol Sci (2016) 0.75
Effects of Asian Dust Particles on the Early-Stage Antigen-Induced Immune Response of Asthma in NC/Nga Mice. Int J Environ Res Public Health (2016) 0.75
Cysteinyl leukotriene receptor 1 mediates LTD4-induced activation of mouse microglial cells in vitro. Acta Pharmacol Sin (2013) 0.75
Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes. J Immunol (2016) 0.75
Cysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer. Oncotarget (2017) 0.75
Critical role of leukotriene B4 receptor signaling in mouse 3T3-L1 preadipocyte differentiation. Lipids Health Dis (2013) 0.75
Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases. Mediators Inflamm (2017) 0.75
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 9.79
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
A comprehensive classification system for lipids. J Lipid Res (2005) 6.52
Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One (2012) 5.03
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00
TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86
Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A (2004) 4.28
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature (2010) 4.12
Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature (2012) 4.04
Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res (2008) 4.01
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem (2003) 3.80
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell (2012) 3.54
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest (2005) 3.44
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med (2004) 3.34
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron (2010) 3.28
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15
Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity (2008) 3.11
Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem (2003) 3.04
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83
The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80
Acyl-CoA:lysophospholipid acyltransferases. J Biol Chem (2008) 2.80
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol (2007) 2.66
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37
Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37
Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol (2006) 2.36
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34
Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol (2008) 2.32
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity (2004) 2.27
Mouse and human neutrophils induce anaphylaxis. J Clin Invest (2011) 2.21
Cloning and characterization of mouse lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. J Biol Chem (2006) 2.18
Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med (2008) 2.17
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet (2004) 2.14
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
Resolvins and protectins in the termination program of acute inflammation. Trends Immunol (2007) 2.06
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol (2013) 1.96
The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 1.96
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest (2011) 1.92
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91
Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med (2006) 1.90
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J (2010) 1.87
Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. Proc Natl Acad Sci U S A (2008) 1.86
Human FcγRIIA induces anaphylactic and allergic reactions. Blood (2011) 1.86
Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension (2002) 1.83
15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med (2009) 1.81
Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol (2013) 1.80
A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem (2006) 1.80
Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science (2007) 1.76
Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta (2010) 1.72
Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am J Hematol (2008) 1.71
Recent progress on acyl CoA: lysophospholipid acyltransferase research. J Lipid Res (2008) 1.71
Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol (2010) 1.70
Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol (2011) 1.69
Unesterified docosahexaenoic acid is protective in neuroinflammation. J Neurochem (2013) 1.68
Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J (2007) 1.67
Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67
Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood (2008) 1.66
Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity (2013) 1.64
Ly6C+ Ly6G- Myeloid-derived suppressor cells play a critical role in the resolution of acute inflammation and the subsequent tissue repair process after spinal cord injury. J Neurochem (2013) 1.60
The use and misuse of Penh in animal models of lung disease. Am J Respir Cell Mol Biol (2004) 1.60
Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci (2011) 1.60
Resolving TRPV1- and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci (2011) 1.58
The resolution of inflammation. Nat Rev Immunol (2012) 1.58
Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. J Allergy Clin Immunol (2002) 1.56
Basic analytical systems for lipidomics by mass spectrometry in Japan. Methods Enzymol (2007) 1.56
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A (2002) 1.54
Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem (2009) 1.53
Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proc Natl Acad Sci U S A (2010) 1.53
Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol (2003) 1.52
Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52
Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol (2008) 1.52
A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom (2005) 1.52
Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.51
Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem (2009) 1.50
G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J Biol Chem (2004) 1.50
A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatography-tandem mass spectrometry. Anal Biochem (2005) 1.49
New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.48
Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J Immunol (2012) 1.48
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol (2010) 1.47